Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, according to results from a stage 3 trial.
The findings, presented at the American College of Cardiology’s Annual Scientific Session in Chicago and published March 29 in the New England Journal of Medicine, showed that patients taking Rybelsus had a lower incidence of heart attacks, strokes and cardiovascular deaths compared to those taking the placebo.
Novo Nordisk has applied for regulatory approval to expand the Rybelsus label to include cardiovascular risk reduction, according to a March 29 news release from the company. The FDA and European Medicines Agency are reviewing the application with a decision anticipated in 2025.
